Literature DB >> 23376360

Non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy.

Hidenori Toyoda1, Takashi Kumada, Toshifumi Tada, Takuro Niinomi, Takanori Ito, Yasuhiro Sone, Yuji Kaneoka, Atsuyuki Maeda.   

Abstract

BACKGROUND & AIMS: The gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) often depicts non-hypervascular hypointense hepatic nodules during the hepatobiliary phase in patients with hepatocellular carcinoma (HCC). It is unclear whether the presence of these nodules is associated with HCC recurrence after hepatectomy. We conducted a prospective observational study to investigate the impact of the presence of non-hypervascular hypointense hepatic nodules on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI on the recurrence of HCC after hepatectomy.
METHODS: A total of 77 patients who underwent hepatectomy for primary, non-recurrent, hypervascular HCC were prospectively followed up after hepatectomy. Post-operative recurrence rates were compared according to the presence of non-hypervascular hypointense nodules on preoperative Gd-EOB-DTPA-enhanced MRI.
RESULTS: Recurrence rates after hepatectomy were higher in patients with non-hypervascular hypointense nodules (risk ratio 1.9396 [1.3615-2.7222]) and the presence of non-hypervascular hypointense nodules was an independent factor associated with postoperative recurrence (risk ratio 2.1767 [1.5089-3.1105]) along with HCC differentiation and portal vein invasion. While no differences were found in the rate of intrahepatic metastasis recurrence based on the preoperative presence of non-hypervascular hypointense hepatic nodules, the rate of multicentric recurrence was significantly higher in patients with preoperative non-hypervascular hypointense hepatic nodules.
CONCLUSIONS: Patients with preoperative non-hypervascular hypointense hepatic nodules detected during the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI are at higher risk of HCC recurrence after hepatectomy, mainly due to multicentric recurrence.
Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23376360     DOI: 10.1016/j.jhep.2013.01.030

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  20 in total

Review 1.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 2.  Insight into hepatocellular carcinoma biology with gadoxetate disodium-enhanced MRI.

Authors:  Alexander Kagen; Kathryn Fowler; Claude B Sirlin
Journal:  Hepat Oncol       Date:  2013-12-20

3.  Breakthrough Imaging in Hepatocellular Carcinoma.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

4.  Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Yasuhiro Sone; Atsuyuki Maeda; Yuji Kaneoka
Journal:  Hepatol Int       Date:  2014-07-23       Impact factor: 6.047

Review 5.  Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI.

Authors:  Ijin Joo; Jeong Min Lee
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

Review 6.  Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

Review 7.  Hepatocellular Carcinoma: Current Imaging Modalities for Diagnosis and Prognosis.

Authors:  Maxime Ronot; Yvonne Purcell; Valérie Vilgrain
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

8.  Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MR can help determine the treatment method for HCC.

Authors:  Dong Ho Lee; Jeong Min Lee; Mi Hye Yu; Bo Yun Hur; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh; Jung-Hwan Yoon; Yoon Jun Kim; Jeong-Hoon Lee; Su Jong Yu; Joon Koo Han
Journal:  Eur Radiol       Date:  2019-01-14       Impact factor: 5.315

Review 9.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

10.  Clinical value of gadoxetic acid-enhanced magnetic resonance imaging in surgery for hepatocellular carcinoma - with a special emphasis on early hepatocellular carcinoma.

Authors:  Masanori Matsuda
Journal:  World J Hepatol       Date:  2015-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.